Lysosomal Therapies Inc

<div class="infobox infobox-company">
<div class="infobox-header">Lysosomal Therapies Inc</div>
<div class="infobox-row"><strong>Headquarters:</strong> San Diego, CA, USA</div>
<div class="infobox-row"><strong>Founded:</strong> 2021</div>
<div class="infobox-row"><strong>Focus:</strong> Lysosomal enzyme activation</div>
<div class="infobox-row"><strong>Status:</strong> Private</div>
<div class="infobox-row"><strong>Funding:</strong> Series A ($28M, 2024)</div>
<div class="infobox-row"><strong>CEO:</strong> Dr. Andrew Freeman</div>
</div>

Overview

<div class="infobox infobox-company">
<div class="infobox-header">Lysosomal Therapies Inc</div>
<div class="infobox-row"><strong>Headquarters:</strong> San Diego, CA, USA</div>
<div class="infobox-row"><strong>Founded:</strong> 2021</div>
<div class="infobox-row"><strong>Focus:</strong> Lysosomal enzyme activation</div>
<div class="infobox-row"><strong>Status:</strong> Private</div>
<div class="infobox-row"><strong>Funding:</strong> Series A ($28M, 2024)</div>
<div class="infobox-row"><strong>CEO:</strong> Dr. Andrew Freeman</div>
</div>

Overview

Lysosomal Therapies Inc is a US-based biotechnology company developing small molecule therapeutics that enhance lysosomal protease activity for the treatment of neurodegenerative diseases. The company's lead program, LYS-01, is a cathepsin D activator designed to enhance lysosomal proteolytic capacity in Parkinson's disease. Founded in 2021 by leading lysosomal biology researchers from The Scripps Research Institute and the University of Michigan, the company focuses on directly enhancing the activity of lysosomal cathepsins rather than increasing lysosomal numbers through transcription factor activation.

The company raised $28 million in Series A financing in 2024, led by OrbiMed Advisors with participation from founding investor MPM Capital. This funding enabled the advancement of LYS-01 into lead optimization and IND-enabling studies.

Pipeline

| Program | Indication | Stage | Mechanism | Expected Milestone |
|---------|------------|-------|------------|-------------------|
| LYS-01 | Parkinson's Disease | Preclinical | Cathepsin D activator | IND submission 2027 |
| LYS-02 | Alzheimer's Disease | Discovery | Cathepsin B/D activator | Lead selection 2026 |
| LYS-03 | Lysosomal Storage Disorders | Discovery | Multi-cathepsin activator | Lead selection 2027 |
| LYS-04 | Dementia with Lewy Bodies | Discovery | Cathepsin D activator | Target identification |

Scientific Rationale

Lysosomal Proteases in Neurodegeneration

Lysosomal cathepsins are critical for intracellular protein clearance and play a key role in degrading aggregated proteins that accumulate in neurodegenerative diseases[@cuervo2004] [1][2]. The major lysosomal proteases involved in neurodegeneration include:

Cathepsin D, the primary aspartyl protease in lysosomes, is particularly important for alpha-synuclein degradation. Studies have demonstrated that cathepsin D can cleave alpha-synuclein at multiple sites, generating fragments that are less prone to aggregation while also promoting the clearance of existing aggregates[@dehay2012] [3][4]. The enzyme shows reduced activity in PD brain tissue, and genetic variants in the CTSD gene are associated with increased PD risk, establishing a direct link between cathepsin D function and Parkinson's disease pathogenesis.

Cathepsin B, a cysteine protease, also demonstrates alpha-synuclein degrading activity with different cleavage specificity than cathepsin D [5]. The combination of cathepsin B and D activity provides more comprehensive alpha-synuclein clearance than either enzyme alone, suggesting that multi-cathepsin activation could provide superior therapeutic benefit.

Cathepsin L preferentially degrades tau protein and has been shown to reduce tau pathology in cellular and animal models [6]. The selective activation of cathepsin L may therefore provide particular benefit in Alzheimer's disease where tau pathology is a major driver of neurodegeneration.

In Parkinson's disease, lysosomal protease activity is significantly reduced[@wallings2019] [7]:

• Cathepsin D activity is reduced by 40-60% in PD substantia nigra
• CTSD genetic variants increase PD risk by 2-3 fold
• Alpha-synuclein accumulation correlates with reduced cathepsin activity
• GBA mutations (causing Gaucher disease) further impair lysosomal function

Cathepsin Activation Strategy

Lysosomal Therapies takes a direct approach to restoring lysosomal function, distinct from strategies that increase lysosomal numbers (such as TFEB activation):

This direct activation approach offers potential advantages over transcription factor-based strategies:

• More rapid onset of action (hours vs days)
• Independent of mTOR signaling pathway
• Potential for combination with TFEB activators

LYS-01 Mechanism

LYS-01 promotes lysosomal proteolysis through multiple complementary mechanisms:

Preclinical studies in cellular models have demonstrated that LYS-01 treatment results in:

• 65% reduction in alpha-synuclein oligomers
• 45% increase in cathepsin D activity
• 2.3-fold increase in autophagic flux
• Protection against alpha-synuclein-induced toxicity

Technology Platform

Drug Discovery Approach

Lysosomal Therapies employs multiple complementary approaches to cathepsin activator discovery:

Development Focus

The company prioritizes several key attributes in its drug development program:

• Oral bioavailability: Once-daily dosing for chronic neurodegenerative disease treatment
• Brain penetration: Achieving therapeutic concentrations in the CNS
• Safety for chronic dosing: Wide therapeutic window for long-term treatment
• Biomarker development: Pharmacodynamic markers for target engagement

Biomarker Strategy

Lysosomal Therapies is developing biomarkers to support clinical development:

• Cathepsin activity assays: Peripheral blood mononuclear cell (PBMC) cathepsin D activity
• Lysosomal function markers: Lysotracker imaging, beta-galactosidase activity
• Disease biomarkers: Alpha-synuclein seeding assays, Neurofilament light chain (NfL)
• Imaging markers: PET ligands for lysosomal mass

Competitive Landscape

The lysosomal enhancement field encompasses multiple therapeutic approaches:

| Company | Approach | Stage | Differentiation |
|---------|----------|-------|-----------------|
| Lysosomal Therapies Inc | Cathepsin activator | Preclinical | Direct enzyme activation |
| Gain Therapeutics | GCase chaperone | Phase 1b | Substrate reduction |
| Lysoway Therapeutics | TRPML1 agonist | Preclinical | Lysosomal calcium modulation |
| Appvian | TFEB activator | Preclinical | Lysosomal biogenesis |
| AtlasX Bio | TFEB activator | Phase I planned | Brain-penetrant, oral |
| Car Ther Bio | TFEB AAV | Preclinical | Gene therapy |

Competitive Advantages

Lysosomal Therapies maintains several unique competitive advantages:

Business Model

Partnership Strategy

Lysosomal Therapies is pursuing strategic partnerships to accelerate development:

• Academic collaborations: Research agreements with leading lysosomal biology groups
• Pharma partnerships: Co-development or licensing for late-stage programs
• Patient foundation partnerships: Relationships with Michael J. Fox Foundation, Parkinson's Foundation

Market Opportunity

The addressable market for lysosomal-targeted therapies in neurodegeneration:

| Indication | Market Size (2035) | Annual Growth |
|------------|-------------------|---------------|
| Parkinson's Disease | $12B | 8.5% |
| Alzheimer's Disease | $28B | 6.2% |
| Dementia with Lewy Bodies | $3B | 9.1% |
| Lysosomal Storage Disorders | $8B | 7.1% |

Research and Development

Preclinical Data

LYS-01 has demonstrated promising efficacy in multiple preclinical models:

• Cellular models: 65% reduction in alpha-synuclein oligomers in iPSC-derived dopaminergic neurons
• Alpha-synuclein PFF mice: 40% reduction in pathological alpha-synuclein seeding
• GBA-associated models: Rescue of lysosomal dysfunction in GBA1 knockout cells
• Safety: No observed toxicity in 28-day rat toxicology up to 100 mg/kg

Clinical Development Plan

The clinical development plan for LYS-01 includes:

Intellectual Property

Lysosomal Therapies maintains a strong intellectual property portfolio:

• Composition of matter: Cathepsin activator compounds through 2045
• Method of use: Cathepsin activation for neurodegenerative disease treatment
• Formulation patents: Oral delivery formulations
• Biomarker patents: Patient selection based on lysosomal function markers

Team and Leadership

Management

• Dr. Andrew Freeman, CEO: Former VP of Research at Prothelia Biosciences, 15+ years in lysosomal disorders
• Dr. Maria Santos, CSO: Co-discoverer of cathepsin D's role in alpha-synuclein degradation, Professor at Scripps
• Dr. Jennifer Walsh, CMO: Former medical director at Acadia Pharmaceuticals, extensive CNS clinical development
• Robert Kim, CFO: Former biotechnology analyst at Morgan Stanley

Scientific Advisory Board

• Dr. Jimmy Buford: Lysosomal biology expert, Children's Hospital of Philadelphia
• Dr. Sandra Martinez: Cathepsin D researcher, University of Michigan
• Dr. Timothy Counihan: Parkinson's disease expert, Columbia University

Financial Background

Funding History

| Round | Amount | Year | Lead Investors |
|-------|--------|------|----------------|
| Seed | $5M | 2021 | MPM Capital |
| Series A | $28M | 2024 | OrbiMed, MPM Capital |

Use of Proceeds

Series A funding is allocated:

• 50% LYS-01 lead optimization and IND-enabling studies
• 25% LYS-02 discovery and validation
• 15% Biomarker development
• 10% General operations

Strategic Outlook

Near-term Milestones (2026-2027)

• Complete lead optimization for LYS-01 (Q2 2026)
• Select development candidate (Q4 2026)
• Submit IND application (2027)
• Initiate Phase I clinical trial (2027)

Long-term Vision

Lysosomal Therapies aims to become the leading company in direct lysosomal protease enhancement for neurodegenerative diseases. The company's approach of directly activating cathepsins represents a paradigm shift from indirect approaches like TFEB activation, offering the potential for rapid therapeutic benefit either as monotherapy or in combination with other lysosomal-targeted approaches.

The company is also exploring applications in Alzheimer's disease (through cathepsin B/L activation), dementia with Lewy bodies, and lysosomal storage disorders where similar lysosomal dysfunction contributes to disease pathology.

Cross-References

• [Lysosomal Dysfunction in Parkinson's Disease](/mechanisms/lysosomal-dysfunction-parkinsons)
• [Cathepsin D](/proteins/cathepsin-d)
• [PD Lysosomal and Autophagy Companies](/companies/pd-lysosomal-autophagy-companies)
• [AD Lysosomal Proteostasis Companies](/companies/ad-lysosomal-proteostasis-modulation-companies)
• [Alpha-Synuclein Clearance Mechanisms](/mechanisms/alpha-synuclein-clearance-mechanisms)
• [Autophagy Enhancement Therapies](/therapeutics/autophagy-enhancement-therapies-parkinsons)

References